for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Windtree Therapeutics Inc

WINT.OQ

Latest Trade

3.67USD

Change

-0.35(-8.71%)

Volume

14,808

Today's Range

3.60

 - 

4.06

52 Week Range

3.60

 - 

10.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.02
Open
4.03
Volume
14,808
3M AVG Volume
0.96
Today's High
4.06
Today's Low
3.60
52 Week High
10.03
52 Week Low
3.60
Shares Out (MIL)
16.92
Market Cap (MIL)
62.10
Forward P/E
-1.75
Dividend (Yield %)
--

Latest Developments

More

Windtree Therapeutics Reports Q3 Loss Per Share $0.54

Windtree Says FDA Acceptance Of Ind Application For A Phase 2 Clinical Trial Studying Kl4 Surfactant In Acute Lung Injury In Adults With Covid-19

Windtree Therapeutics Files For Mixed Shelf Of Upto $75 Mln - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Windtree Therapeutics Inc

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Industry

Biotechnology & Drugs

Contact Info

2600 Kelly Rd Ste 100

WARRINGTON, PA

18976-3652

United States

+1.215.4889300

http://www.windtreetx.com/

Executive Leadership

James Z. Huang

Independent Chairman of the Board

Craig E. Fraser

President, Chief Executive Officer, Director

John P. Hamill

Chief Financial Officer, Senior Vice President

Eric L. Curtis

Chief Operating Officer, Senior Vice President

Joseph Soffer

Executive Vice President - Clinical Development

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2020(E)

0.0K
EPS (USD)

2020(E)

-2.095
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
23.86
LT Debt To Equity (MRQ)
22.93
Return on Investment (TTM)
-33.05
Return on Equity (TTM)
-29.65

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up